Provocative results suggest lower BP targets may be advisable for CAD patients.
Provocative new findings suggest that for patients with established CAD, the answer is yes. And physicians might want to carefully consider which antihypertensive drug to use in such patients as well. Results from the just-released CAMELOT trial show that significant benefit in reduced morbidity and mortality could be riding on this decision. While more research on this matter is clearly in order, experts contend there is already ample room for improvement in BP management--even with current targets.